Clinical trials for Glioma

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 43881 clinical trials with a EudraCT protocol, of which 7295 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (196)
Paediatric studies in scope of Art45 of the Paediatric Regulation (85)

196 result(s) found for: Glioma. Displaying page 1 of 10.

EudraCT Number: 2008-001438-29

Sponsor Protocol Number: 427/08

Start Date*: 2008-05-15

Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Full Title: NGF for visual blindness in patient affected by glioma

Medical condition: gloma with visual blindness

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10030935	Optic nerve glioma	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2011-003030-14

Sponsor Protocol Number: 758/11

Start Date*: 2012-09-03

Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Full Title: Nerve Growth Factor (NGF) eye drop administration as visual rescue treatment in visual loss-associated optic gliomas.

Medical condition: Glioma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10030953	Optic tract glioma	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2015-003362-84

Sponsor Protocol Number: FSJD-DIPG-DC

Start Date*: 2016-05-18

Sponsor Name:Fundació Sant Joan de Déu

Full Title: Phase Ib clinical trial on the safety of immunotherapy with autologous dendritic cells primed with lysate allogeneic tumor lines in patients with diffuse intrinsic pontine glioma ( DIPG )

Medical condition: Diffuse intrinsic pontine glioma (DIPG)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006143	Brain stem glioma	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2017-001307-68

Sponsor Protocol Number: 68Ga-PSMA-GLIOMI-2016

Start Date*: 2017-11-07

Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI

Full Title: ¿THE NOVEL 68Ga-PSMA THERANOSTIC PET/CT COMPOUND FOR FUNCTIONAL IMAGING OF GLIOMA¿ "IMPIEGO DELL¿INNOVATIVO TRACCIANTE TERANOSTICO 68Ga-PSMA PER L¿IMAGING FUNZIONALE PET/TC DEL GLIOMA "

Medical condition: Suspicion of glioma on the basis of clinical and RM data, where histological confirmation is provided, as is the normal care pathway.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018338	Glioma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2015-002185-23

Sponsor Protocol Number: DIPG

Start Date*: 2015-07-29

Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"

Full Title: Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concom...

Medical condition: diffuse intrinsic pontine glioma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006143	Brain stem glioma	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2016-000758-37

Sponsor Protocol Number: NO18517

Start Date*: 2016-08-23

Sponsor Name:F. Hoffmann-La Roche AG

Full Title: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas

Medical condition: High Grade Glioma Brainstem Glioma

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006143	Brain stem glioma	PT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018338	Glioma	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: Outside EU/EEA

Trial results: View results

EudraCT Number: 2008-003714-10

Sponsor Protocol Number: 947

Start Date*: 2008-06-13

Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Full Title: Intensity Modulated Radiotherapy with Simultaneous Boost plus Temozolomide in high grade gliomas

Medical condition: high grade gliomas

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10018338	Glioma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000636-40

Sponsor Protocol Number: PNOC022

Start Date*: 2022-10-20

Sponsor Name:Pacific Pediatric Neuro-Oncology Consortium (PNOC)

Full Title: PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initi...

Medical condition: Diffuse Midline Gliomas, H3K27M mutant

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065443	Malignant glioma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006143	Brain stem glioma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10080666	Diffuse intrinsic pontine glioma	LLT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2007-001768-60

Sponsor Protocol Number: CNS 2007 04

Start Date*: 2007-10-01

Sponsor Name:University of Birmingham

Full Title: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide with Radiotherapy in Diffuse Pontine Gliomas

Medical condition: Diffuse pontine glioma in children

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006143	Brain stem glioma	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2016-002417-21

Sponsor Protocol Number: AK2016-2

Start Date*: 2016-09-22

Sponsor Name:Rigshospitalet

Full Title: uPAR-PET/MR in glioma

Medical condition: Gliomas

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018337	Glioblastoma multiforme	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018338	Glioma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002599-35

Sponsor Protocol Number: 2022-1-58-002

Start Date*: 2022-10-21

Sponsor Name:Centre de Lutte Contre le Cancer Eugène Marquis

Full Title: Contribution of [18F]DPA-714 PET for grading and exploration of the inflammatory microenvironment of glioma, a pilot study.

Medical condition: glioma (grade OMS II à IV)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018338	Glioma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2015-002307-28

Sponsor Protocol Number: GBMTMZ/DOX2015

Start Date*: Information not available in EudraCT

Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER

Full Title: An open-label, single-center, single-arm Phase II study to evaluate safety and efficacy of doxorubicin in combination with radiotherapy, temozolomide and valproic acid in patients with glioblastoma...

Medical condition: Glioblastoma multiforme, diffuse intrisic pontine glioma, diffuse glioma of the brain stem and spinal cord, bilateral thalamic glioma, gliomatosis cerebri, anaplastic astrocytoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10018338	Glioma	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2009-012582-64

Sponsor Protocol Number: 337/09

Start Date*: 2009-07-29

Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Full Title: Treatment with bevacizumab and irinotecan in patients with recurrent or refractory high grade glioma after conventional treatment.

Medical condition: high grade glioma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10065443	Malignant glioma	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2010-018447-34

Sponsor Protocol Number: 06MH34

Start Date*: 2011-09-22

Sponsor Name:Great Ormond Street Hospital for Children NHS Trust

Full Title: Investigation of dendritic cell vaccine immunotherapy in paediatric high grade glioma

Medical condition: Paediatric High grade glioma, excluding brain stem gliomas

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065443	Malignant glioma	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2004-000464-28

Sponsor Protocol Number: 904

Start Date*: 2005-01-20

Sponsor Name:Ark Therapeutics Limited

Full Title: A Controlled, Randomised, Parallel Group, Multicentre Study of the Efficacy and Safety of Herpes Simplex Virus-Thymidine Kinase Gene Therapy (CereproTM), with Subsequent Ganciclovir, for the Treatm...

Medical condition: Operable high grade primary or recurrent glioma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	7.0		10018338		PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed) CZ (Completed) FI (Completed) BE (Completed)

Trial results: (No results available)

EudraCT Number: 2007-005644-24

Sponsor Protocol Number: BERTES-01

Start Date*: 2007-11-27

Sponsor Name:AMC-UvA

Full Title: Bevacizumab, Radiotherapy and Temozolomide Safety study in resected and irresectable primary GBM patients

Medical condition: Primary Glioblastoma Multiforme

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10018338	Glioma	LLT
	9.1		10018336	Glioblastoma	LLT
	9.1		10065443	Malignant glioma	LLT

Population Age:

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-004125-23

Sponsor Protocol Number: CCRG19-002

Start Date*: 2021-05-10

Sponsor Name:Antwerp University Hospital

Full Title: Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma

Medical condition: Childhood high-grade glioma and diffuse intrinsic pontine glioma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004865	10046859	Vaccination	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006143	Brain stem glioma	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10080666	Diffuse intrinsic pontine glioma	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: BE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2009-016870-33

Sponsor Protocol Number: CILENT-0902

Start Date*: 2010-05-20

Sponsor Name:Centre Oscar Lambret

Full Title: Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study

Medical condition: Newly diagnosed diffuse intrinsic pontine glioma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	12.1		10006143	Brain stem glioma	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2009-015036-15

Sponsor Protocol Number: AVIRMA

Start Date*: 2010-01-21

Sponsor Name:Medizinische Universität Innsbruck - Universitätsklinik für Neurologie

Full Title: Avastin / Irinotecan in patients with recurrent or progressive malignant glioma An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging techni...

Medical condition: First or second tumour recrurrence/progression of a histological confirmed supratentorial malignant glioma WHO Grade III-IV

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	12.0		10065443	Malignant glioma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: AT (Completed)

Trial results: View results

EudraCT Number: 2016-001045-12

Sponsor Protocol Number: NO21125

Start Date*: 2016-07-20

Sponsor Name:F. Hoffmann-La Roche AG

Full Title: A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas.

Medical condition: Intrinsic Brainstem Glioma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006143	Brain stem glioma	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: Outside EU/EEA

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA